

Revision date: 05-Jan-2012 Version: 1.0 Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Folic Acid Tablets

Trade Name: Folacin Chemical Family: Mixture

Intended Use: Folic acid deficiency

2. HAZARDS IDENTIFICATION

Appearance: Yellow tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: Not acutely toxic (based on components)

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including

effects on gastrointestinal disturbances and abdominal pain.

EU Indication of danger: Not classified

Australian Hazard Classification

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Folic Acid	59-30-3	200-419-0	Not Listed	5***
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Povidone	9003-39-8	Not Listed	Not Listed	*

PZ01686

Material Name: Folic Acid Tablets Page 2 of 6
Revision date: 05-Jan-2012 Version: 1.0

Nevision date. 05-5an-2012

Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	*
Calcium phosphate dibasic, anhydrous	7757-93-9	231-826-1	Not Listed	*

Additional Information: * Proprietary

*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Folic Acid Tablets Page 3 of 6 Revision date: 05-Jan-2012 Version: 1.0

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken,

> avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or

environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other

equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³ Australia TWA 10 ma/m³ 10 mg/m³ **Belgium OEL - TWA Estonia OEL - TWA** 10 mg/m³ France OEL - TWA 10 mg/m³ Ireland OEL - TWAs 10 mg/m³ 4 mg/m³ Latvia OEL - TWA 2 mg/m^3 **OSHA - Final PELS - TWAs:** 15 mg/m³ Portugal OEL - TWA 10 mg/m³ Romania OEL - TWA 10 mg/m³ 10 mg/m³ Spain OEL - TWA

Calcium phosphate dibasic, anhydrous

Latvia OEL - TWA 10 mg/m³

Magnesium stearate

10 mg/m³ **ACGIH Threshold Limit Value (TWA)** 5 mg/m³ Lithuania OEL - TWA Sweden OEL - TWAs 5 mg/m³

Folic Acid

Pfizer Occupational Exposure OEB 3 (control exposure to the range of >10ug/m³ to < 100ug/m³)

Band (OEB):

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Refer to applicable national standards and regulations in the selection and use of personal **Personal Protective Equipment:**

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Wear safety glasses or goggles if eye contact is possible. Eyes:

Impervious protective clothing is recommended if skin contact with drug product is possible and Skin:

for bulk processing operations.

Material Name: Folic Acid Tablets

Revision date: 05-Jan-2012

Page 4 of 6

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:TabletsColor:YellowMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m³

Povidone

Rat Oral LD50 100 g/kg

Folic Acid

Mouse Oral LD 50 10 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Povidone

IARC: Group 3 (Not Classifiable)

Material Name: Folic Acid Tablets

Revision date: 05-Jan-2012

Page 5 of 6

Version: 1.0

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

Folic Acid

Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present

Material Name: Folic Acid Tablets

Revision date: 05-Jan-2012

Page 6 of 6

Version: 1.0

15. REGULATORY INFORMATION

Standard for the Uniform SchedulingSchedule 2for Drugs and Poisons:Schedule 4EU EINECS/ELINCS List200-419-0

Povidone

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
232-674-9

Sodium starch glycolate

Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present

Calcium phosphate dibasic, anhydrous

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

231-826-1

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
209-150-3

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Prepared by:Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
